Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of tamibarotene in autosomal dominant polycystic kidney disease
jRCT2011230055Phase 2Active, not recruiting
- Sponsor
- Rege Nephro Co., Ltd.
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Tamibarotene with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2023; status: active, not recruiting.
02
Drugs
tamibarotene
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2011230055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230055.